Latest News
Biogen Issues Q2 Community Statement on Spinraza
Dear members of the SMA community, We are grateful for the opportunity to continue to help support individuals with spinal muscular atrophy (SMA), their caregivers and families. We deeply appreciate […]
Read More ›Team Cure SMA Celebrates Global Running Day!
Happy Global Running Day! Is Global Running Day a made-up holiday? Kind of. But unlike other made-up holidays dedicated to eating pancakes or taking selfies, Global Running Day has the […]
Read More ›Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
Scholar Rock today announced positive final top-line results from the Phase 1 clinical trial of its product candidate, SRK-015, a highly specific inhibitor of myostatin activation, in healthy adult volunteers. […]
Read More ›Cure SMA to Host “Evening in the Park” at Disneyland Thanks to Support from AveXis
Conference attendees will enjoy a magical “Evening in the Park” at Disneyland thanks to special support from AveXis, a Novartis company. All registered attendees for the family conference will receive […]
Read More ›AveXis and Cure SMA to Co-Host Webinar on the FDA’s Approval of Zolgensma
On Wednesday, June 12th, at 10am CDT (8am PDT/9am MDT/11am EDT) AveXis, a Novartis company, and Cure SMA will co-host a webinar on the FDA approval of Zolgensma. This webinar […]
Read More ›AveXis Issues Community Statement on Zolgensma Approval
Dear SMA Community, We have exciting news to share with you — a major milestone has been reached in the fight against spinal muscular atrophy (SMA)! The US Food and […]
Read More ›